# Exicure, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Exicure, Inc). ## Overview Exicure, Inc. is a U.S.-based early-stage biotechnology company that historically developed nucleic acid therapies, but has since halted research and development and is now focused on strategic alternatives. The company has monetized parts of its legacy intellectual property through licensing and asset sales, while also pursuing financing and other transactions to preserve optionality. ## Products & services • Legacy nucleic acid therapy intellectual property • Patent licenses for historical drug candidates • Royalty rights from licensed biotechnology assets • Asset sales of historical biotech IP and related samples • Strategic alternatives / corporate restructuring activities - **Biotechnology IP licensing** (60%) — Licensing of patents and related rights tied to historical drug candidates and technologies. - **Asset monetization** (25%) — Sale of legacy biotechnology assets, samples, and other non-core IP holdings. - **Royalty income** (10%) — Potential future royalties from licensed technologies, subject to third-party commercialization. - **Corporate and strategic transactions** (5%) — Financing, acquisitions, partnerships, and other strategic alternatives to preserve value. - Legacy nucleic acid therapy intellectual property - Patent licenses for historical drug candidates - Royalty rights from licensed biotechnology assets - Asset sales of historical biotech IP and related samples - Strategic alternatives and restructuring transactions ## Customers Exicure’s direct counterparties are primarily biopharmaceutical companies that license patents or acquire assets tied to its historical programs. In the current phase, the company is less of a product seller and more of an IP holder seeking monetization through licensing, royalties, and transaction structures. Any future economic value depends on third parties advancing the licensed technologies or on successful strategic transactions. - **Biopharmaceutical licensees** (primary) — Companies that license Exicure patents or technology to develop and commercialize drug candidates. - **Asset purchasers** (primary) — Buyers of legacy intellectual property, samples, and other non-core biotech assets. - **Strategic transaction counterparties** (secondary) — Potential acquirers, partners, or investors involved in restructuring or value-maximizing deals. - **Future royalty payers** (emerging) — Commercial partners whose product sales could trigger modest royalty streams. - Private clinical-stage biopharmaceutical companies licensing hepatitis rights - Partners acquiring legacy biotech IP and related assets - Potential acquirers in strategic alternatives or private transactions - Future commercializers whose sales could generate royalties - Financing counterparties providing equity or convertible capital ## Geography Exicure is headquartered in the United States and its reported business activity is centered there. The company’s current operations are primarily domestic, with counterparties and financing activity also appearing to be U.S.-based. Because the company is in a monetization and restructuring phase, geography matters mainly through access to U.S. capital markets, legal processes, and domestic biotech partners. - United States is the core operating and financing base - Legacy IP monetization and licensing activity is U.S.-centric - No meaningful country revenue disclosure was provided - U.S. capital markets access is critical for survival - Domestic legal and regulatory costs are a material operating burden ## Strategy Exicure’s strategy is no longer centered on internal drug development; it is focused on preserving value through strategic alternatives, licensing, asset sales, and external financing. Management is trying to monetize legacy intellectual property while maintaining enough liquidity to continue operating and evaluate transactions. The company’s near-term direction is driven by survival, optionality, and the possibility of a restructuring or sale. - **Secure financing** (short-term) — Liquidity is insufficient to fund obligations and strategic exploration. - **Complete strategic alternatives** (short-term) — The company needs a transaction path to preserve or realize remaining value. - **Monetize legacy IP** (medium-term) — Licensing and royalties are the main remaining sources of potential value. - Pursue strategic alternatives to maximize stockholder value - Monetize legacy IP through licenses, royalties, and asset sales - Seek additional capital to fund ongoing operations - Evaluate partnerships, acquisitions, and other transactions - Preserve optionality while legacy R&D remains halted ## Risks Exicure faces severe going-concern risk because current liquidity is not sufficient to fund operations, and management has disclosed the possibility of bankruptcy or cessation of operations. The business also depends on uncertain licensing, royalty, and transaction proceeds that are outside its control, while any new capital raise could be highly dilutive. As a small biotech shell with limited revenue, it is also exposed to legal, regulatory, and public-company overhead that can overwhelm remaining resources. - **Going-concern and liquidity shortfall** [critical] — Cash is not sufficient to fund obligations and operations without new financing. - **Financing dilution and restrictive terms** [high] — Future capital may come from equity or convertible debt with dilution or covenants. - **Uncertain monetization of legacy IP** [high] — Royalties and license fees depend on third-party development and commercialization. - **Public-company and legal cost burden** [medium] — Administrative, regulatory, accounting, and IT costs remain despite limited operations. - **Biotech development and commercialization risk** [medium] — Any remaining value depends on assets in a highly uncertain drug-development sector. - Going-concern risk due to insufficient liquidity - Potential bankruptcy or cessation of operations - Dilution risk from equity or convertible financing - Uncertain royalty and license income timing - High fixed public-company and legal overhead ## Accounting The most important accounting issues are fair value measurement of contingent liabilities, impairment of long-lived assets, and valuation of acquired biotech intangibles. The company also has judgment-heavy estimates around business combinations and discounted cash flow assumptions, which can materially affect reported assets and earnings. Because revenue is limited and non-recurring, small changes in licensing or settlement accounting can have outsized effects on quarterly results. - **Contingent liability fair value** — Other income/expense volatility - **Long-lived asset impairment** — Potential write-downs - **Business combination valuation** — Goodwill/intangible valuation and amortization - **License revenue recognition** — Lumpy revenue and margin timing - Fair value changes in contingent liability affect other income/expense - Long-lived asset impairment depends on future cash flow assumptions - Business combination valuation uses judgment-heavy DCF and MPEEM inputs - License and royalty revenue may be lumpy and non-recurring - One-time gains and settlements can distort quarterly comparability --- *Last updated: 2026-04-28T20:04:04.736733+00:00*